Clearstead Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10 Buy
+5
New +$10 ﹤0.01% 3473
2022
Q4
– Sell
-82
Closed – – 1317
2022
Q3
$0 Hold
82
– – ﹤0.01% 1254
2022
Q2
$0 Hold
82
– – ﹤0.01% 1282
2022
Q1
$0 Hold
82
– – ﹤0.01% 1375
2021
Q4
$0 Hold
82
– – ﹤0.01% 1284
2021
Q3
$1K Hold
82
– – ﹤0.01% 1179
2021
Q2
$1K Buy
+82
New +$1.62K ﹤0.01% 1123

Other funds holding BDTX

Clearstead Advisors's BDTX Position: Q3 2026 in Review

Clearstead Advisors opened a new position in Black Diamond Therapeutics (BDTX) in Q3 2026: 5 shares worth $10. The stake represents ﹤0.01% of the portfolio and ranks #3473 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in BDTX as recently as Q3 2022.

Clearstead Advisors first reported a position in BDTX in Q2 2021 and has held it in 7 quarters since. The position peaked at $1K in Q3 2021. 110 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.

  • Clearstead Advisors held 5 shares of Black Diamond Therapeutics worth $10 as of Q3 2026.
  • Black Diamond Therapeutics was a new Clearstead Advisors position in Q3 2026.
  • Black Diamond Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q3 2026, its #3473 holding.
  • Clearstead Advisors first reported a position in Black Diamond Therapeutics in Q2 2021 and has held it in 7 quarters since.
  • Clearstead Advisors's Black Diamond Therapeutics position peaked at $1K in Q3 2021.
  • 110 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.

Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.